Abstract #4733

Oxygen-Enhanced MOLLI T1 Mapping during Chemoradiotherapy in Anal Squamous Cell Carcinoma

Emma Bluemke¹, Daniel Bulte¹, Ambre Bertrand¹, Ben George², Rosie Cooke², Kwun-Ye Chu³, Lisa Durrant², Vicky Goh⁴, Clare Jacobs², Stasya Ng⁵, Victoria Strauss⁶, Maria Hawkins³, and Rebecca Muirhead²

¹Institute of Biomedical Engineering, University of Oxford, Oxford, United Kingdom, ²Department of Oncology, Oxford University Hospitals Trust, Oxford, United Kingdom, ³Radiotherapy Department, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, ⁴Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, Oxford, United Kingdom, ⁵Cancer Imaging, School of Biomedical Engineering & Imaging Sciences, King's College London, London, United Kingdom, ⁶Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom

Early identification of patients in need of radiotherapy treatment intensification would allow tailored radiotherapy dose. We hypothesize that patients with poor vascularity or hypoxia will correlate with these patients, and T1 changes from oxygen-enhanced MRI could provide indications of tumour perfusion. We acquired T1-maps before and after 8-10 fractions of radiotherapy and examined whether the oxygen-enhanced MRI response relates to clinical outcome. There was a significant increase in tumour T1 across patients following chemoradiotherapy (p<0.001). Before chemoradiotherapy, OE-MRI showed no significant changes in tumour T1, however after receiving chemoradiotherapy, OE-MRI showed a significant decrease in tumour T1 (p<0.001).

This abstract and the presentation materials are available to members only; a login is required.

Join Here